Physician profile
Nancy Ho
NPI 1154554657
$1,696.82
in general payments reported to CMS, 2019-2025
14 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $480 · 2023: $316 · 2024: $248 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.08 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.76 | 2021-2022 | |
| Medtronic, INC. | $129.53 | 2022-2025 | Gi Genius |
| Janssen Biotech, INC. | $97.06 | 2023-2025 | Stelara, Tremfya, Remicade |
| Braintree Laboratories, INC. | $95.33 | 2023-2025 | Suflave, Sutab |
| Lilly USA, LLC | $64.82 | 2024 | Omvoh |
| Qol Medical, LLC | $45.19 | 2023-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $43.60 | 2025 | Vegzelma |
| Olympus America INC. | $39.97 | 2024 | Endoclot Phs |
| Takeda Pharmaceuticals U.S.A., INC. | $31.64 | 2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $28.17 | 2023 | Ocaliva |
| Gilead Sciences, INC. | $25.69 | 2025 | |
| Genzyme Corporation | $25.15 | 2023 | |
| Pfizer INC. | $21.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.